Mentalization-Based Treatment versus Specialist Treatment as Usual for Borderline Personality Disorder: Economic Evaluation alongside a Randomized Controlled Trial with 36 Months Follow-Up

Matthijs Blankers^{a,b,c}, David Koppers^a, Elisabeth M. P. Laurensen^{d,e}, Jaap Peen^a, Maaïke L. Smits^e, Patrick Luyten^{f,g}, Jan Busschbach^{e,h}, Jan H. Kamphuisⁱ, Martijn Kikkert^a, Jack Dekker^a

- a. Arkin Mental Health Care, Klaprozenweg 111, 1033 NN, Amsterdam, The Netherlands.
- b. Trimbos-Institute, Netherlands Institute of Mental Health and Addiction, Da Costakade 45, 3521 VS, Utrecht, The Netherlands.
- c. Academic Medical Center, Department of Psychiatry, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
- d. Dutch Knowledge Centre for Child and Adolescent Psychiatry, Catharijnesingel 47, 3511 GC, Utrecht, The Netherlands.
- e. Viersprong Institute, Studies on Personality Disorders, Peter Vineloolaan 50, 4611 AN, Bergen op Zoom, The Netherlands.
- f. Faculty of Psychology and Educational Sciences, University of Leuven, Belgium.
- g. Research Department of Clinical, Educational and Health Psychology, University College London, UK.
- h. Department of Psychiatry, Section Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands.
- i. Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands.

Author note

This research was supported in part by a grant from ZonMW, the Netherlands Organization for Health Research and Development (grant no. 171002402).

Patrick Luyten has been involved in the training and dissemination of mentalization-based treatments. The other authors declare that they have no competing interests.

Correspondence concerning this article should be addressed to Matthijs Blankers, Arkin Mental Health Care, Department of Research, PO Box 75848, 1070 AV Amsterdam, The Netherlands. Email: matthijs.blankers@arkin.nl.

Abstract

This paper presents an economic evaluation performed alongside a randomized controlled trial of Mentalization-Based Treatment in a Day Hospital setting (MBT-DH) versus specialist treatment as usual (S-TAU) for borderline personality disorder (BPD) with a 36-month follow-up period. Ninety-five patients from two Dutch treatment institutes were randomly assigned. Societal costs were compared with the proportion of BPD remissions and quality-adjusted life years (QALYs) measured using the five-dimensional EuroQol instrument. The incremental societal costs for one additional QALY could not be calculated. The costs for one additional BPD remission with MBT-DH are approximately €29,000. There was a 58% likelihood that MBT-DH leads to more remitted patients at additional costs compared with S-TAU, and a 35% likelihood that MBT-DH leads to more remissions at lower costs. MBT-DH is not cost-effective compared with S-TAU with QALYs as the outcome, and slightly more cost-effective than S-TAU at 36 months with BPD symptoms as the outcome.

Keywords: Economic evaluation, mentalization-based treatment, borderline personality disorder, randomized controlled trial.

Mentalization-Based Treatment versus Specialist Treatment as Usual for Borderline Personality Disorder: Economic Evaluation alongside a Randomized Controlled Trial with 36 Months Follow-Up

Borderline personality disorder (BPD) is one of the most prevalent mental disorders in psychiatric populations (Paris, 2010; Leichsenring et al., 2011) and is associated with low quality of life (Soeteman et al., 2008b), high psychiatric comorbidity (Zanarini, 1998; Skodol, et al., 1999; Trull et al., 2000; Barrachina et al., 2011), and, in addition, high socioeconomic burden (Soeteman et al., 2008a; Laurensen et al., 2016). In pure monetary terms, the projected annual average societal costs for a BPD patient based on 2014 prices is approximately €15,000 per year, based on work by Soeteman et al. (2008a; €13,088 in the year 2005) and Laurensen et al. (2016; €16,879 per year).

International treatment guidelines (Dutch Committee of Guideline-Development for Mental Health Care, 2008; National Institute for Health and Clinical Excellence, 2009) and a Cochrane review (Stoffers et al., 2012) suggest that Mentalization-Based Treatment (MBT; Bateman & Fonagy, 2004) in a day hospital setting (MBT-DH) or in an outpatient setting is a preferred treatment for BPD, given the strong evidence base, which for BPD is exceeded by only by that for Dialectical Behavior Therapy (DBT; Stoffers et al., 2012). MBT is a psychodynamic treatment based on attachment and mentalizing approaches. Mentalizing refers to the capacity to interpret the self and others in terms of internal mental states such as feelings, emotions, wishes, desires, attitudes, and values (Laurensen et al., 2014). The first randomized controlled trial (RCT) of MBT was conducted by Bateman and Fonagy (see Bateman & Fonagy, 1999, 2001, 2008). This first RCT was criticized for its lack of a competitive therapy as a control and the role of the developers of MBT themselves as the primary investigators. Subsequently, the developers performed RCTs with a competitive control condition, again showing favourable results for outpatient MBT (Bateman & Fonagy, 2009; Rossouw & Fonagy, 2012; Robinson et al., 2016). RCTs independent of the developers of MBT have shown more modest results (Jørgensen et al., 2013, 2014). A matched-control design study (Bales et al., 2015) confirmed the effectiveness of MBT up to 36 months follow-up.

There are still few studies on the cost-effectiveness of MBT. Favorable economic outcomes were presented by Bateman and Fonagy (2003) based on their RCT, showing that during treatment the

costs of MBT were similar to the control condition, whereas costs in the MBT condition were substantially lower after treatment completion. A problem with the interpretation of these results was that the control intervention was not specifically aimed at BPD; furthermore, the economic evaluation performed by Bateman and Fonagy (2003) was not performed according to state-of-the art guidelines for cost-effectiveness studies. Attempts to replicate these results using more conventional methods led to results surrounded by uncertainty (Brazier, 2006). Therefore, a state-of-the-art health economic evaluation of MBT using a relevant control condition and a long-term follow-up is needed.

In 2018, Laurensen et al. conducted an RCT independently of the developers of MBT and concluded that MBT-DH was equally as effective as Specialist Treatment as Usual (S-TAU) at 18-month follow-up. Recently, the 36-month follow-up data from this RCT became available. These data allow us to test whether initial higher costs of MBT are offset by lower costs and better clinical outcomes at long-term follow-up. A cost-effectiveness study by Soeteman et al. (2010) with a 5-year time horizon revealed the contrary, that is, that the higher treatment costs of day-hospital treatments for BPD, including MBT, are not offset by a reduction in costs of healthcare utilization and productivity losses when compared with outpatient treatment, at a willingness-to-pay threshold of €40,000 per quality-adjusted life year (QALY). According to the Netherlands Health Care Institute, a willingness-to-pay threshold of €50,000 is more suitable for patients with a disease burden comparable to the studied population (Zorginstituut Nederland, 2015). Over a 5-year time horizon, day hospitalization was more effective in terms of QALYs and more cost-effective, at a price of €56,325 per QALY, compared with outpatient care—just above the €50,000 threshold. Thus, it might be possible that, especially in the long term, MBT-DH is more cost effective than S-TAU.

In the current paper we present an economic evaluation performed alongside the RCT by Laurensen et al. (2018), which compared the costs and effects of MBT-DH and S-TAU over a 36-month follow-up period. The evaluation consists of a cost-utility analysis from a societal perspective, in which the utilities have been expressed in QALYs. To align with the more traditional outcomes in psychology and psychiatry, we have also performed a cost-effectiveness analysis in which the effects have been expressed as the proportion of patients having a low/subthreshold (≤ 15) Borderline Personality Disorder Severity Index version IV (BPDSI) score (Arntz et al., 2003).

Method

For the design and reporting of this economic evaluation, we adhered to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (Husereau et al., 2013) and to the ISPOR guideline for economic evaluation alongside RCTs (Ramsey et al., 2015).

Participants, allocation, and assessments

Participants were 95 patients meeting the criteria for a BPD diagnosis as assessed by the Structured Clinical Interview for DSM-IV Axis II Personality disorders (SCID-II) (Weertman et al., 2000), and a total score on the BPDSI (Arntz et al., 2003) of at least 20, reflecting severe BPD. All patients had been referred to one of two mental healthcare institutes in Amsterdam (Arkin or De Viersprong). Exclusion criteria were schizophrenia, bipolar disorder, substance use disorders requiring specialist treatment, organic brain disorder, IQ <80, and inadequate mastery of the Dutch language. Patients who met the inclusion criteria and provided written informed consent were randomly assigned to receive MBT-DH or S-TAU. Patients completed the baseline BPDSI before randomization and before diagnosis; all other baseline assessments were completed after randomization and after diagnosis. Treatment started at around the time the baseline assessments were completed. Follow-up interviews and assessments were conducted every 6 months until 36 months follow-up. The protocol of this study has been published elsewhere (Laurensen et al., 2014). This study was approved by a Medical Ethics Review Committee in the Netherlands and is registered in the trial register as # NL26308.097.09, and complied with the Helsinki Declaration 1975, as revised in 2008.

Interventions

MBT-DH comprises an intensive day-hospitalization programme of a maximum of 18 months followed by up to 18 months of maintenance mentalizing (group) therapy. The day-hospital program, which takes place for 6 hours per day, 5 days per week, includes (a) implicit mentalizing groups (daily group psychotherapy and weekly individual psychotherapy, and individual crisis planning from a mentalizing perspective) and (b) explicit mentalizing groups (art therapy twice a week, mentalizing cognitive group therapy, and writing therapy). Each week ends with a social hour and a community meeting. Patients can also consult a psychiatrist once a week and medication is offered according to American Psychiatric Association guidelines. The treatment aims of MBT-DH are to (a) engage

patients in treatment; (b) reduce psychiatric symptoms, particularly self-harm and parasuicidal behaviour; (c) improve social and interpersonal functioning; and (d) foster more appropriate healthcare usage and prevent hospital admissions and (prolonged) inpatient care. To achieve this, components of MBT-DH focus on enhancing the patients' mentalizing capacity (Laurensen et al., 2014).

S-TAU comprises mainly outpatient manualized treatments for patients with severe personality disorders, with varying treatment length and duration. S-TAU is an eclectic intervention, consisting of supporting and structuring sessions, extensive diagnostic investigations, writing a crisis plan, family interventions, STEPPS (Blum et al., 2008) or Linehan training, social skills training, aggression/impulse regulation training, cognitive schema-focused or traditional insight-oriented treatment, pharmacotherapy, and/or inpatient treatment. If possible, patients in the S-TAU condition are treated by the Municipality Mental Health Crisis Service; otherwise, patients are referred to other treatments that meet their specific needs and wishes (see Laurensen et al., 2014 for more details). However, S-TAU patients did not receive MBT, and the S-TAU intervention is less intensive than the MBT-DH intervention in terms of engagement and time spent in therapy.

Resource use and valuation

Healthcare utilization, use of medication, and productivity losses were measured using the first section of the Trimbos Questionnaire for Costs associated with Psychiatric illness (TiC-P) (Hakkaart-van Roijen et al., 2002). This instrument is validated for economic evaluations in populations of psychiatric patients (Bouwman et al., 2013). Using this section of the TiC-P, the number of contacts with health professionals and the frequency of informal care were collected for the 6-month period before the follow-up interviews. The TiC-P has a 4-week recall period, which was linearly extrapolated to the 6-month period between the consecutive follow-up interviews, in line with the approach used by Hakkaart-van Roijen et al. (2007). Using the TiC-P, all healthcare contacts except MBT-DH- or S-TAU-related healthcare contacts were collected, as the MBT-DH and S-TAU contacts were collected from the electronic patient records of the two participating treatment centers.

Standard unit cost prices for the Netherlands (Zorginstituut Nederland, 2016) were used to value healthcare resource utilization by multiplying the number of contacts with the reference costs per contact. Medication costs were valued based on the reported medication use. Frequency of

medication use was assumed to be daily unless otherwise noted. Unit costs per dose of medication were extracted from the Netherlands Ministry of Health registry for cost prices of medication (Farmatec, 2016).

The second section of the TiC-P is the Short Form-Health and Labor Questionnaire (SF-HLQ). This questionnaire assesses whether the participant has worked in the previous 2 weeks and whether he/she has been absent from work (absenteeism) or has functioned suboptimally at work due to illness (presenteeism). Productivity losses in hours were multiplied by an estimate of averaged labor costs of €37.90 for men and €31.60 for women (Zorginstituut Nederland, 2016). Productivity losses were valued using the friction cost method, with a maximum friction costs period of 85 days (based on Zorginstituut Nederland, 2016) and an elasticity factor of 0.8 (Koopmanschap et al., 1995). Another source of public costs assessed in this economic evaluation is the use of justice system resources. We collected all self-reported police and justice-related contacts of patients, and valued these contacts according to the justice system costs valuation by Drost et al. (2014).

All future costs as seen from the date of randomization were discounted at an annual rate of 4% (Zorginstituut Nederland, 2016). Dutch unit prices were converted to Organisation for Economic Co-operation and Development (OECD) standard purchasing power parities for the study's index year, 2014 (123% for the Netherlands) (OECD, 2019).

Effect measures

The effect measure for the cost-utility analysis was the number of QALYs gained between the time of randomization and 36-month follow-up. The three-level, five-dimensional EuroQol (EQ-5D-3L) quality of life instrument was used (EuroQol Group, 1990). The EQ-5D-3L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with three levels: no problems, some problems, and extreme problems. Using the Dutch EQ-5D tariff (Lamers et al., 2006), the raw EQ-5D-3L scores were converted to health utilities. Using the area under the curve method with linear interpolation, the repeated measures of these health utilities over the 36-month follow-up period were integrated into a number of QALYs gained or lost for each participant. Future QALYs have been discounted at a rate of 1.5% per year (Zorginstituut Nederland, 2016). The effect measure for the cost-effectiveness analysis was the proportion of patients having a

BPDSI score ≤ 15 at the 36-month follow-up. The BPDSI scale has a range of 0–90, with higher scores representing greater severity (Giesen-Bloo et al., 2010). The ≤ 15 criterion has been proposed as the clinical cut-off score (Giesen-Bloo et al., 2010); hence, patients with a score of 15 or lower are considered to have remitted.

Data preparations

All analyses were performed on an intention-to-treat basis. Missing observations in costs and effects data were handled using multiple imputation (with 50 imputations for each missing observation). Imputations were performed using the package Amelia II v. 1.7.5 (Honaker et al., 2018). In the base case analysis, missing data were assumed to be missing at random (MAR). The MAR pattern is conventionally assumed when applying common missing data approaches such as multiple imputation. Cost parameters were square root transformed before imputation and back-transformed to the original scale afterwards, to take the skewed distribution of these variables into account. First, analyses were performed on the imputed datasets separately. The outcomes of the 50 imputations were then combined using Rubin's rules (Rubin, 1987). All presented results are based on the multiple imputed data, unless otherwise indicated. We used the R statistical programming environment for all analyses.

Cost-effectiveness calculations

For all participants, we multiplied units of healthcare (e.g., sessions, contacts, and medication), productivity losses due to absenteeism or presenteeism, and contacts with the justice system (e.g. days of incarceration) by their associated costs. Differences in costs and effects between MBT-DH and S-TAU were calculated as the difference in cumulative costs and effects over the 36-month period of this study. In order to present the development over time of the costs and effects for the two interventions in terms of BPDSI score, remissions, quality of life, and societal costs from baseline to 36-month follow-up, generalized linear mixed models were fitted.

Next, we extracted a total of 2,500 nonparametric bootstrapped samples from the imputed data, with a number of patients per trial arm equal to the number of patients in the original dataset. For each of these bootstrapped samples, we calculated the incremental costs, incremental effects, and incremental cost-effectiveness ratio (ICER). The ICER was calculated as follows: $ICER = (Costs_{MBT-DH} - Costs_{S-TAU}) / (Effects_{MBT-DH} - Effects_{S-TAU})$.

$_{DH} - \text{Costs}_{S-TAU}) / (\text{Effects}_{MBT-DH} - \text{Effects}_{S-TAU})$, where effects were either QALYs or remission rates based on BPDSI scores. These data were also plotted on cost-effectiveness planes, which present the differences in costs and effects between MBT-DH and S-TAU in two dimensions by plotting costs against effects. The reference intervention (S-TAU) is positioned in the origin of the cost-effectiveness plane. Based on the distribution of the ICERs over the cost-effectiveness plane, cost-effectiveness acceptability curves (CEACs; van Hout, 1994) were drawn. CEACs show the probability that MBT-DH is more cost-effective than S-TAU as a function of the willingness to pay for 1 additional unit of effect (1 additional QALY or 1 additional person whose BPD remitted). Willingness to pay can be €50,000 per QALY in the Netherlands for an intermediate burden of disease, such as BPD (Zwaap et al., 2015).

Base case, alternative scenarios, and sensitivity analyses

The base case scenario of this economic evaluation was performed from the societal perspective, using the data imputed under the MAR assumption. The societal perspective implies that all available costs were included, that is, BPD treatment costs, medication costs, all other healthcare costs, losses or gains in productivity of each patient, and patients' justice resource costs. In addition to this base case scenario analysis, we performed three alternative analyses. In the first, the societal perspective was taken but this time missing data were imputed under the Missing Completely At Random (MCAR) assumption, which postulates that missing observations are randomly drawn from the available data (Rubin, 1987). MCAR imputations were performed using the "random sample draw" option in the imputation package mice v. 2.30 (van Buuren & Groothuis-Oudshoorn, 2011) for R. Differences between MCAR and MAR may indicate that drop-out affected the representativeness of the final sample. The second alternative analysis evaluated the cost-effectiveness of MBT-DH versus S-TAU from the healthcare sector perspective. In this analysis, BPD treatment costs, medication costs, and all other healthcare costs were included. The last alternative analysis took the narrowest costs perspective and accounted for BPD treatment costs only. In order to assess the sensitivity of our findings to misspecification of costs, one-way sensitivity analyses were performed to evaluate the impact on the ICERs of a -20% to +20% misspecification in the abovementioned cost categories.

Results

Descriptive statistics

Table 1 presents the participants' baseline characteristics. Differences between MBT-DH and S-TAU were tested using *t*-tests and Pearson's chi-squared test with Monte Carlo simulated *p*-values where we had to deal with a low number of participants. None of the characteristics listed in Table 1 differed significantly between the two study conditions at baseline. Supplementary Table S1 presents a comparison of the data completeness of the two study conditions over time.

Costs

Table 2 presents the cumulative societal mean costs during the trial from baseline to 36-month follow-up. The median psychiatric hospitalization costs associated with BPD treatment were significantly lower in MBT-DH, whereas the day hospital costs associated with BPD treatment and overall treatment costs associated with BPD were significantly higher in MBT-DH, compared to S-TAU. In addition, medication costs were significantly lower in MBT-DH, whereas other healthcare costs, productivity costs and justice resources costs were significantly lower in S-TAU. Overall, the overall societal costs were slightly higher in MBT-DH. Figure S1 in the supplementary online materials gives more information about the societal costs for the MBT-DH and S-TAU group for each assessment point.

Effects

Table 3 presents the effects of the MBT-DH and the S-TAU interventions in terms of quality of life and BPDSI score, from baseline to 36-month follow-up. The time $\times$ group interactions for EQ-5D NL score ($p = 0.56$) and for QALYs ($p = 0.31$) were not statistically significant. The BPDSI scale scores in both conditions declined over time. Generalized linear mixed model analysis, with sex, gender, age, and treatment centre as covariates, a random intercept for patients, and a random slope for time within patients, indicated a significant time $\times$ group interaction ($B = -1.388$, $SE = 0.475$, $t(234.4) = 2.919$, $p = 0.004$). This interaction effect indicated that the decline in BPDSI score was stronger for the MBT-DH group than the S-TAU group. No time $\times$ group interaction effect was found for the proportion of patients whose BPD remitted ($p = 0.10$); for this model, a binomial link function was applied. For the societal costs, a significant time $\times$ group interaction was found ($B = -1001$, $SE =$

356.1, $t(16,363) = 2.81$, $p = 0.005$), indicating that the development of societal cost over time was different for the MBT-DH and S-TAU conditions—as can also be seen in supplementary Figure S1.

Cost-utility and cost-effectiveness

Table 4 presents the results of the cost-utility and cost-effectiveness analysis. Figure 1 shows the cost-effectiveness planes and the CEACs associated with the base case scenario.

With regard to the cost-utility analysis, from Table 4 it can be observed that the ICER for one additional QALY could not be calculated, as for this effect measure MBT-DH is dominated by S-TAU: patients receiving MBT-DH costed more and gained fewer QALYs than S-TAU patients. This finding is further illustrated by the cost-effectiveness plane for QALYs. It can be observed from Figure 1 that there is a 57% likelihood that MBT-DH is dominated by S-TAU (north-west quadrant), and a 35% likelihood that MBT-DH could be cost-saving (i.e. leading to less QALYs at lower societal costs; south-west quadrant). The likelihood that MBT-DH dominates S-TAU with regard to costs per QALY is negligible (3%). The CEAC for QALYs indicates that the higher the willingness to pay per QALY, the lower the likelihood that MBT-DH would be preferred over S-TAU in terms of costs per QALY.

Regarding the cost-effectiveness analysis, the ICER for one additional remission with MBT-DH compared with S-TAU is approximately €29,000 in the base case scenario (Table 4). In the scenario where only healthcare costs are taken into account and other societal costs (e.g. productivity costs, justice resources costs) are ignored, the ICER per additional remission with MBT-DH is approximately €22,000. With multiple imputation under the MAR assumption, we attempted to reduce the impact of missing data on the representativeness of the final sample. The results under the (less likely) MCAR missing data scenario are somewhat different from the results under the MAR scenario.

Based on the top left panel in Figure 1, it can be observed that under the base case scenario there is a 58% likelihood that MBT-DH leads to more patients whose BPD remitted at additional societal costs compared with S-TAU. There is a 35% likelihood that MBT-DH dominates S-TAU, which means that it leads to more remissions at lower societal costs per patient. The likelihood that MBT-DH is dominated by S-TAU (fewer remissions at higher costs) is almost negligible at 5%. Based on the CEAC, assuming that there is no willingness to pay more for extra remissions than in the

current situation under S-TAU, there may be a preference for S-TAU (63%), while at a willingness to pay of €45,000 extra over a period of 36 months for one extra remitted patient, there is a small preference (55%) for MBT-DH.

Sensitivity analyses

Figure 2 presents the results for the sensitivity scenarios, in order to assess the stability of the results under incorrect specification of the cost drivers of the model. The plot indicates what the ICER with remission as an outcome would have been if the cost drivers on the vertical axis had been 20% higher or 20% lower than in the base case scenario. If BPD hospitalization costs were 20% higher or BPD day care costs were 20% lower than were assumed in our base case model, the ICER would have been lower and MBT-DH would have been more attractive in terms of costs per remission. If BPD hospitalization costs were 20% lower or BPD day care costs were 20% higher than assumed in our base case model, the opposite would have been true, and S-TAU would have been more attractive. All other cost drivers had limited impact on the incremental cost per remission.

Discussion

In this paper, we have evaluated the cost-utility and cost-effectiveness of MBT-DH compared with S-TAU among BPD patients. Key findings are that MBT-DH is dominated by S-TAU with QALYs as the outcome, while MBT-DH is potentially cost-effective compared with S-TAU with remissions as the outcome. The median incremental cost per incremental remission (€29,000 over 36 months, or almost €10,000 per year) is somewhat lower than the estimated costs to society of a patient with unremitted BPD (approximately €15,000 per year; see Soeteman et al., 2008a; Laurensen et al., 2016). At a willingness to pay of €45,000 over a 36-month period for a remitted patient, there is a 55% likelihood that MBT-DH is the more cost-effective of the two interventions, and hence a 45% likelihood that S-TAU is the more cost-effective. Although the numerical results varied, the negative results for MBT-DH in the cost-utility outcome and the favourable results in the cost-effectiveness outcome remained stable under the alternative scenarios and in sensitivity analyses.

The finding that MBT-DH was slightly superior to S-TAU in terms of cost-effectiveness with remissions as the outcome may seem out of line with the clinical results of the comparison between MBT-DH and S-TAU by Laurensen et al. (2018). In that study, both MBT-DH and S-TAU showed

significant improvements on all outcome measures at 18-month follow-up, but MBT-DH was not superior to S-TAU. The difference between the present cost-effectiveness study and the effectiveness study of Laurensen et al. (2018) is that in the present study effects are measured over a 36-month follow-up, while Laurensen et al. reported on only the first 18 months of follow-up. A number of studies have found that MBT can be more effective after a long period than a short period of follow-up (see, e.g., Bateman & Fonagy, 1999, 2001, 2008, 2009; Smits et al., 2019).

The finding that remission and QALY outcomes did not correspond was unexpected, especially as Cramer et al. (2007) showed that personality disorders in general and BPD traits are negative determinants of quality of life. However, a similar discrepancy was reported in an economic evaluation of schema-focused therapy versus transference-focused psychotherapy for BPD being treated in an outpatient setting using the EQ-5D-3L (van Asselt et al., 2008). These authors discussed their findings in the context of a potential difference in responsiveness of the EQ-5D and the BPDSI, but in a subsequent paper they showed that the EQ-5D is fairly responsive in BPD (van Asselt et al., 2009). Furthermore, Soeteman et al. (2010, 2011) used the EQ-5D in the economic evaluation of treatments for personality disorders, with consistent results.

In our study, the EQ-5D and BPDSI were only weakly correlated, with $r = 0.34$ on average over the seven time points (range: $r = 0.11$ at baseline to $r = 0.44$ at 36 months). It should be noted that correlations at baseline will always be low, due to the restriction of range through the inclusion and exclusion criteria, but even at follow-up the association was weak. A further inspection of Spearman correlations between the individual EQ-5D items and the BPDSI indicated that EQ-5D items 1 (“Problems walking about”) and 4 (“Pain or discomfort”) correlated poorly ($r = 0.08$ and 0.09 , respectively) with the BPDSI total score, while the only psychiatry-related item, item 5 (“Feeling anxious or depressed”) correlated somewhat better ($r = 0.40$). Hence, a difference in scores between EQ-5D items and BPDSI may be caused by the fact that the former instrument seems to measure health (improvement) on multiple independent dimensions, which are not all equally impacted by BPD symptoms. Another possible explanation on the divergence between BPDSI and EQ-5D-3L is that MBT-DH is more focused on the reduction of borderline symptoms than S-TAU, while S-TAU is more focused on quality-of-life-related skills, via, for example, psychosocial skills and family

interventions. This explanation is in line with the meta-analysis by Newton-Howes et al. (2014), as they hypothesized that a poorer response on a certain dimension is related to a lack of focus on that dimension in treatment. Additionally, the Collaborative Longitudinal Personality Disorders Study (Skodol et al., 2005) and the McLean Study of Adult Development (Zanarini et al., 2005) indicate that symptomatic improvement often does not lead to social and functional improvement (see also Levy, 2008).

This study has several limitations. First, there was quite substantial drop-out. Although we have addressed this statistically using multiple imputation, it may still have impacted our findings due to selective drop-out. Evidence of the presence of selective drop-out and its influence can be found in the variations in results based on the two different imputation strategies. The differences between the results based on the two imputation strategies do not, however, lead to substantively different conclusions. Second, although the relatively long-term follow-up and seven repeated measurements made this trial especially suitable for an economic evaluation, it was not originally powered to find statistical differences in cost data. Hence, all reported findings are probabilistic in nature, with uncertainty around all parameters. In addition, the unit costs used in the analyses are obtained from costing manuals, and may be different from the actual costs accrued or paid by healthcare organizations, insurance companies, or other stakeholders, and in other countries. Third, although the study was a multicenter RCT, we do not know to what extent the results would generalize outside the treatment contexts in which the study took place. Additional studies are needed to further support our findings and to clarify the nature of the association between the two presented outcome parameters. A fourth limitation is that MBT-DH was provided by a newly set up treatment service, and hence implementation issues may have mitigated the treatment effects of MBT-DH. Although therapists trained in MBT were highly experienced clinicians, they had almost no prior experience with MBT. By contrast, S-TAU was well established and administered by professionals with years of experience with their approach (Laurensen et al., 2018).

Taking into consideration the limitations of this study, we found that MBT-DH is not preferred to S-TAU at 36 months with QALYs as the outcome of the cost-utility analysis, and slightly more cost-effective than S-TAU at 36 months when the effect parameter is the likelihood of BPD

remission. The fact that there may be a paradoxical impact on overall quality of life is something that indicates a need for more research, and potentially to consider add-on interventions to address aspects of quality of life that are not addressed satisfactorily by MBT-DH.

Acknowledgements

We would like to thank Laura Bakker, Carolien Christ, and Isabel Alvarez Perez for their hard work in collecting the data. We are also very grateful to all the patients who participated in this study.

References

- Arntz, A., van den Hoorn, M. A., Cornelis, J., Verheul, R., van den Bosch, W. M. C., de Bie, A. J. H. T. (2003). Reliability and validity of the Borderline Personality Disorder Severity Index. *Journal of Personality Disorders*, 17, 45-59.
- Bales, D. L., Timman, R., Andrea, H., Busschbach, J. J., Verheul, R., Kamphuis, J. H. (2015). Effectiveness of Day Hospital Mentalization-Based Treatment for Patients with Severe Borderline Personality Disorder: A Matched Control Study. *Clinical Psychology & Psychotherapy*, 22, 409-417.
- Barrachina, J., Pascual, J. C., Ferrer, M., Soler, J., Rufat, M. J., Andión, O., Tiana, T., Martín-Blanco, A., Casas, M., Pérez, V. (2011). Axis II comorbidity in borderline personality disorder is influenced by sex, age, and clinical severity. *Comprehensive Psychiatry*, 52, 725-730.
- Bateman, A., Fonagy, P. (1999). The effectiveness of partial hospitalization in the treatment of borderline personality disorder: A randomized controlled trial. *American Journal of Psychiatry*, 156, 1563-1569.
- Bateman, A., Fonagy, P. (2001). Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: An 18-month follow-up. *American Journal of Psychiatry*, 158, 36-42.
- Bateman, A., Fonagy, P. (2003). Health service utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. *American Journal of Psychiatry*, 160, 169-171.
- Bateman, A., Fonagy, P. (2004). *Psychotherapy for borderline personality disorder: Mentalization-Based Treatment*. Oxford University Press: Oxford.

- Bateman, A., Fonagy, P. (2008). 8-year follow-up of patients treated for borderline personality disorder: Mentalization-based treatment versus treatment as usual. *American Journal of Psychiatry*, 165, 631-638.
- Bateman, A., Fonagy, P. (2009). Randomized controlled trial of outpatient Mentalization-Based Treatment versus structured clinical management for borderline personality disorder. *American Journal of Psychiatry*, 166, 1355-1364.
- Blum, N., St John, D., Pfohl, B., Stuart, S., McCormick, B., Allen, J., Arndt, S., Black, D. W. (2008). Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. *American Journal of Psychiatry*, 165, 468-478.
- Bouwman, C., de Jong, K., Timman, R., Zijlstra-Vlasveld, M., Van der Feltz-Cornelis, C., Tan Swan, S., Hakkaart-van Roijen, L. (2013). Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). *BMC Health Services Research*, 13, 217.
- Brazier, J., Tumor, I., Holmes, M., Ferriter, M., Parry, G., Dent-Brown, K., Paisley, S. (2006). Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation. *Health Technology Assessment*, 10, 1-117.
- Cramer, V., Torgersen, S., Kringlen, E. (2007). Socio-demographic conditions, subjective somatic health, Axis I disorders and personality disorders in the common population: the relationship to quality of life. *Journal of Personality Disorders*, 21, 552-567.
- Drost, R. M. W. A., Paulus, A. T. G., Ruwaard, D., Evers, S. M. A. A. (2014). *Handleiding intersectorale kosten en baten van (preventieve) interventies: Classificatie, identificatie en kostprijzen [Manual intersectoral costs and benefits of (preventive) interventions: Classification, identification and unit costs]*. Maastricht University: Maastricht.

- Dutch Committee of Guideline-Development for Mental Health Care (2008). *Multidisciplinaire richtlijn persoonlijkheidsstoornissen versie 1 [Multidisciplinary guideline personality disorders version 1]*. Trimbos-instituut: Utrecht.
- EuroQol Group (1990). EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy*, 16, 199-208.
- Farmatec (2016). *Prijslijst vaststelling herijking 40 [Pricelist determination and recalibration 40]*. Ministerie van Volksgezondheid Welzijn en Sport/CIBG: Den Haag.
<https://www.farmatec.nl/prijsvorming/documenten>. Accessed October 3, 2018.
- Giesen-Bloo, J. H., Wachers, L. M., Schouten, E., Arntz, A. (2010). The borderline personality disorder severity index IV: Psychometric evaluation and dimensional structure. *Personality and Individual Differences*, 49, 136-141.
- Hakkaart-van Roijen, L., van Straten, A., Donker, M., Tiemens, B. (2002). *Handleiding Trimbos/iMTA questionnaire for Costs associated with Psychiatric illness (TiC-P) [Manual Trimbos/iMTA questionnaire for Costs associated with Psychiatric illness (TiC-P)]*. iMTA/Trimbos Instituut: Rotterdam.
- Hakkaart-van Roijen, L., Zwirs, B. W., Bouwmans, C., Tan, S. S., Schulpen, T. W., Vlasveld, L., Buitelaar, J. K. (2007). Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). *European Child & Adolescent Psychiatry*, 16, 316-326.
- Honaker, J., King, G., Blackwell, M. (2018). *Amelia II: a Program for Missing Data. Version 1.7.5*.
<https://cran.r-project.org/web/packages/Amelia/vignettes/amelia.pdf>. Accessed October 3, 2018.
- Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., Loder, E., CHEERS Task Force. (2013). Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *Value in Health*, 16, e1-5.
- Jørgensen, C. R., Bøye, R., Andersen, D., Døssing Blaabjerg, A. H., Freund, D., Jordet, H., Kjølbye, M. (2014). Eighteen months post-treatment naturalistic follow-up study of mentalization based

- therapy and supportive group treatment of borderline personality disorder: Clinical outcomes and functioning. *Nordic Psychology*, 66, 254-273.
- Jørgensen, C. R., Freund, C., Boye, R., Jordet, H., Andersen, D., Kjølbye, M. (2013). Outcome of mentalization-based and supportive psychotherapy in patients with borderline personality disorder: a randomized trial. *Acta Psychiatrica Scandinavica*, 127, 305-317.
- Koopmanschap, M. A., Rutten, F. F., van Ineveld, B. M., van Roijen, L. (1995). The friction cost method for measuring indirect costs of disease. *Journal of Health Economics*, 14, 171-189.
- Lamers, L. M., McDonnell, J., Stalmeier, P. F., Krabbe, P. F., Busschbach, J. J. (2006). The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. *Health Economics*, 15, 1121-1132.
- Laurensen, E. M., Eeren, H. V., Kikkert, M. J., Peen, J., Westra, D., Dekker, J. J., Busschbach, J. J. V. (2016). The burden of disease in patients eligible for mentalization-based treatment (MBT): quality of life and costs. *Health and Quality of Life Outcomes*, 14, 145.
- Laurensen, E. M. P., Luyten, P., Kikkert, M. J., Westra, D., Peen, J., Soons, M. B. J., van Dam, A. M., van Broekhuizen, A. J., Blankers, M., Busschbach, J. J. V., Dekker, J. J. M. (2018). Day hospital mentalization-based treatment v. specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. *Psychological Medicine*, 26, 1-8.
- Laurensen, E. M., Westra, D., Kikkert, M. J., Noom, M. J., Eeren, H. V., van Broekhuizen, A. J., Peen, J., Luyten, P., Busschbach, J. J., Dekker, J. J. M. (2014). Day Hospital Mentalization-Based Treatment (MBT-DH) versus treatment as usual in the treatment of severe borderline personality disorder: protocol of a randomized controlled trial. *BMC Psychiatry*, 14, 149.
- Leichsenring, F., Leibing, E., Kruse, J., New, A. S., Leweke, F. (2011). Borderline personality disorder. *Lancet*, 377, 74-84.
- Levy, K. N. (2008). Psychotherapies and lasting change. *American Journal of Psychiatry*, 165, 556-559.
- National Institute for Health and Clinical Excellence (NICE) (2009). *Borderline personality disorder: Treatment and management*. NICE: London.

Newton-Howes, G., Tyrer, P., Johnson, T., Mulder, R., Kool, S., Dekker, J., Schoevers, R. (2014).

Influence of personality on the outcome of treatment in depression: systematic review and meta-analysis. *Journal of Personality Disorders*, 28, 577-593.

OECD (2019). Prices: Purchasing Power Parities for GDP and related indicators. *Main Economic Indicators (database)*. <https://doi.org/10.1787/data-00608-en>. Accessed May 1, 2019.

Paris, J. (2010). Estimating the prevalence of personality disorders in the community. *Journal of Personality Disorders*, 24, 405-411.

Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A., Sullivan, S. D. (2015). Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. *Value in Health*, 18, 161-72.

Robinson, P., Hellier, J., Barrett, B., Barzdaitiene, D., Bateman, A., Bogaardt, A., Clare, A., Somers, N., O'Callaghan, A., Goldsmith, K., Kern, N., Schmidt, U., Morando, S., Ouellet-Courtois, C., Roberts, A., Skårderud, F., Fonagy, P. (2016). The NOURISHED randomised controlled trial comparing mentalisation-based treatment for eating disorders (MBT-ED) with specialist supportive clinical management (SSCM-ED) for patients with eating disorders and symptoms of borderline personality disorder. *Trials*, 17, 549.

Rossouw, T. I., Fonagy, P. (2012). Mentalization-based treatment for self-harm in adolescents: A randomized controlled trial. *Journal of the American Academy of Child and Adolescent Psychiatry*, 51, 1304-1313.

Rubin, B. D. (1987). *Multiple Imputation for Nonresponse in Surveys*. John Wiley & Sons: New York.

Skodol, A. E., Gunderson, J. G., Shea, M. T., McGlashan, T. H., Morey, L. C., Sanislow, C. A., Bender, D. S., Grilo, C. M., Zanarini, M. C., Yen, S., Pagano, M. E., Stout, R. L. (2005). The Collaborative Longitudinal Personality Disorders Study (CLPS): overview and implications. *Journal of Personality Disorders*, 19, 487-504.

Skodol, A. E., Stout, R. L., McGlashan, T. H., Grilo, C. M., Gunderson, J. G., Tracie Shea, M., Morey, L. C., Zanarini, M. C., Dyck, I. R., Oldham, J. M. (1999). Co-occurrence of mood and personality disorders: A report from the collaborative longitudinal personality disorders study (CLPS). *Depression and Anxiety*, 10, 175-182.

- Smits, M. L., Feenstra, D. J., Eeren, H. V., Bales, D. L., Laurensen, E. M. P., Blankers, M., Soons, M. B. J., Dekker, J. J. M., Lucas, Z., Verheul, R., Luyten, P. (2019). Day hospital versus intensive out-patient mentalisation-based treatment for borderline personality disorder: multicentre randomised clinical trial. *British Journal of Psychiatry*, in press.
- Soeteman, D. I., Hakkaart-van Roijen, L., Verheul, R., Busschbach, J. J. (2008a). The economic burden of personality disorders in mental health care. *Journal of Clinical Psychiatry*, 69, 259-265.
- Soeteman, D. I., Verheul, R., Busschbach, J. J. V. (2008b). The burden of disease in personality disorders: Diagnosis-specific quality of life. *Journal of Personality Disorders*, 22, 259-268.
- Soeteman, D. I., Verheul, R., Delimon, J., Meerman, A. M. M. A., van den Eijnden, E., Rossum, B. V., Ziegler, U., Thunnissen, M., Busschbach, J. J. V., Kim, J. J. (2010). Cost-effectiveness of psychotherapy for cluster B personality disorders. *British Journal of Psychiatry*, 196, 396–403.
- Soeteman, D. I., Verheul, R., Meerman, A. M. M. A., Rossum, B. V., Delimon, J., Rijnierse, P., Thunnissen, M., Busschbach, J. J. V., & Kim, J. J. (2011). Cost-effectiveness of psychotherapy for cluster C personality disorders: a decision-analytic model in the Netherlands. *Journal of Clinical Psychiatry*, 72, 51-59.
- Stoffers, J. M., Vollm, B. A., Rucker, G., Timmer, A., Huband, N., Lieb, C. (2012). Psychological therapies for people with borderline personality disorder. *Cochrane Database of Systematic Reviews*, 8, 1-255.
- Trull, T. J., Sher, K. J., Minks-Brown, C., Durbin, J., Burr, R. (2000). Borderline personality disorder and substance use disorders: A review and integration. *Clinical Psychology Review*, 20, 235-253.
- van Asselt, A. D., Dirksen, C. D., Arntz, A., Giesen-Bloo, J. H., van Dyck, R., Spinhoven, P., van Tilburg, W., Kremers, I. P., Nadort, M., Severens, J. L. (2008). Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy. *British Journal of Psychiatry*, 192, 450-457.

- van Asselt, A. D., Dirksen, C. D., Arntz, A., Giesen-Bloo, J. H., Severens, J. L. (2009). The EQ-5D: A useful quality of life measure in borderline personality disorder? *European Psychiatry*, 24, 79-85.
- van Buuren, S., Groothuis-Oudshoorn, K. (2011). mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*, 45, 1-67.
- van Hout, B. A., Al, M. J., Gordon, G. S., Rutten, F. F. (1994). Costs, effects and C/E-ratios alongside a clinical trial. *Health Economics*, 3, 309-319.
- Weertman, A., Arntz, A., Kerkhofs, M. L. M. (2000). *SCID II: gestructureerd klinisch interview voor DSM-IV As-II persoonlijkheidsstoornissen [SCID II: Structured clinical interview for DSM-IV Axis II personality disorders]*. Harcourt Test Publishers: Amsterdam.
- Zanarini, M. C. (1998). Axis I comorbidity of borderline personality disorder. *American Journal of Psychiatry*, 155, 1733-1739.
- Zanarini, M. C., Frankenburg, F. R., Hennen, J., Reich, D. B., Silk, K. R. (2005). The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up. *Journal of Personality Disorders*, 19, 505-23.
- Zorginstituut Nederland (2015). *Kosteneffectiviteit in de praktijk [Cost-effectiveness in practice]*. Zorginstituut Nederland: Diemen.
- Zorginstituut Nederland (2016). *Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg [Guideline for economic evaluations in health care]*. Zorginstituut Nederland: Diemen.
- Zwaap, J., Knies, S., van der Meijden, C., Staal, P., van der Heiden, L. (2015). *Kosteneffectiviteit in de praktijk [Cost-effectiveness in Practice]*. Zorginstituut Nederland: Diemen.

Tables

Table 1. Baseline demographic and clinical characteristics of the study participants

	MBT-DH (<i>n</i> = 54)	S-TAU (<i>n</i> = 41)	χ^2 <i>t</i> (<i>df</i>)	<i>p</i>
Age; mean (<i>SD</i>)	34.3 (9.5)	34.0 (10.6)	<i>t</i> (80.9) = 0.13	0.89
Gender; <i>n</i> (%)			$\chi^2(1) = 0.10$	0.8
Female	42 (77.8 %)	33 (80.5 %)		
Education; <i>n</i> (%) ^a			$\chi^2(8) = 6.77$	0.49
Low / other	5 (9.4 %)	5 (12.2 %)		
Medium	23 (43.4 %)	20 (48.8 %)		
High	25 (47.2 %)	16 (39.0 %)		
Trial site; <i>n</i> (%)			$\chi^2(1) = 0.01$	1.00
Arkin	36 (66.7 %)	27 (65.9 %)		
Viersprong	18 (33.3 %)	14 (34.1 %)		
Marital status; <i>n</i> (%)			$\chi^2(6) = 6.53$	0.28
Married	3 (5.6 %)	1 (2.4 %)		
Divorced	4 (7.4 %)	5 (12.2 %)		
Partner relationship	5 (9.3 %)	2 (4.9 %)		
Living together	4 (7.4 %)	5 (12.2 %)		
Single	38 (70.4 %)	25 (61.0 %)		
Other	0 (0 %)	3 (7.3 %)		
Vocational status; <i>n</i> (%) ^b			$\chi^2(8) = 3.77$	0.74
Employed	13 (26.0 %)	5 (12.5 %)		
Unemployed	27 (54.0 %)	27 (67.5 %)		
Student	2 (4.0 %)	1 (2.5 %)		
Other	8 (16.0 %)	7 (17.5 %)		
BPDSI total score; mean (<i>SD</i>)	34.4 (8.3)	32.8 (7.1)	<i>t</i> (91.7) = 1.03	0.31
EQ-5D score; mean (<i>SD</i>)	0.42 (0.33)	0.39 (0.27)	<i>t</i> (65.5) = 0.42	0.67
All healthcare costs; mean (<i>SD</i>)	6 203 (9 531)	4 926 (9 008)	<i>t</i> (88.0) = 0.66	0.51
Productivity costs; mean (<i>SD</i>)	500 (1 930)	572 (2 156)	<i>t</i> (80.9) = 0.17	0.87

Note. MBT-DH= Day Hospital Mentalization-Based Treatment; S-TAU = Specialist Treatment As

Usual; BPDSI = Borderline Personality Disorder Severity Index version IV; EQ-5D = three-level, five-dimensional EuroQol with the Dutch health utilities algorithm applied (Lamers et al., 2006).

^a *n* = 53 (MBT-DH), the original nine levels have been reduced to three levels, for χ^2 test the nine-level data have been used.

^b *n* = 50 (MBT-DH); *n* = 40 (S-TAU), the original nine levels have been reduced to four levels, for χ^2 test the nine-level data have been used.

Table 2. Mean costs and bootstrapped incremental mean costs per cost category

Cumulative cost	MBT-DH (n = 54)		S-TAU (n = 41)		Incremental costs (95% CI)		
	<i>Mean (€)</i>	<i>SD</i>	<i>mean (€)</i>	<i>SD</i>	<i>Median</i>	<i>Lower CI</i>	<i>Upper CI</i>
BPD hospitalization	3,988	10,721	19,620	56,858	-15,623	-18,202	-13,228
BPD day hospital	21,130	10,396	2,589	5,169	18,543	18,099	18,979
BPD outpatient care	12,949	13,122	12,145	13,402	802	54	1,555
BPD treatment (total)	38,067	21,750	34,354	57,016	3,712	1,089	6,273
Medication	2,576	1,858	2,711	1,935	-135	-242	-25
Other healthcare	20,571	20,391	22,240	17,730	-1,668	-2,752	-572
Productivity	1,596	4,141	1,217	2,949	379	180	582
Justice resources	1,310	2,335	619	1,135	692	593	791
Overall societal costs	64,121	29,463	61,141	66,171	2,973	-71	6,011

Note. MBT-DH = Day Hospital Mentalization-Based Treatment; S-TAU = Specialist

Treatment As Usual; Other healthcare refers to all other healthcare costs (psychiatric and/or somatic) not directly related to MBT-DH or S-TAU BPD treatment; presented costs are the full costs accrued between baseline and 36-month follow-up. CI is the confidence interval around the median. Some numbers may not add up due to rounding and bootstrapping. Due to the skewed distributions of costs, the standard deviation likely overestimates the variation in costs.

Table 3. Intervention effects and societal costs per outcome assessment wave

<i>Measure</i>	<i>Time (months)</i>	MBT-DH		S-TAU	
		<i>Mean</i> %	<i>SD</i>	<i>Mean</i> %	<i>SD</i>
BPDSI score	Baseline	34.4	8.29	32.8	7.08
	6	29.8	11.45	25.4	10.29
	12	25.4	11.65	24.8	10.07
	18	21.5	11.03	22.4	9.64
	24	19.2	10.17	21.9	10.07
	30	18.2	9.45	22.9	10.32
	36	19.5	11.12	23.7	10.09
BPDSI ≤15 (Remission)	Baseline	0.0 %		0.0 %	
	6	9.4 %		13.6 %	
	12	15.8 %		18.1 %	
	18	29.4 %		24.7 %	
	24	38.0 %		25.5 %	
	30	40.0 %		25.6 %	
	36	33.4 %		19.6 %	
EQ-5D NL score	Baseline	0.408	0.340	0.404	0.284
	6	0.398	0.328	0.490	0.320
	12	0.413	0.352	0.476	0.316
	18	0.452	0.354	0.509	0.313
	24	0.443	0.345	0.510	0.343
	30	0.432	0.340	0.515	0.323
	36	0.472	0.375	0.555	0.316
QALYs (cumulative)	Baseline	0	0	0	0
	6	0.200	0.138	0.221	0.116
	12	0.402	0.270	0.455	0.222
	18	0.618	0.394	0.691	0.311
	24	0.842	0.506	0.941	0.399
	30	1.060	0.605	1.119	0.489
	36	1.287	0.715	1.471	0.571
Societal costs	Baseline	€6,697	€9,728	€5,708	€9,303
	6	€14,714	€6,254	€9,737	€11,267
	12	€13,367	€9,222	€10,332	€12,202
	18	€9,580	€7,484	€10,033	€14,714
	24	€7,234	€5,820	€8,665	€10,502
	30	€6,655	€5,339	€8,426	€10,918
	36	€5,872	€5,296	€8,240	€11,955

Note. BPDSI score = Borderline Personality Disorder Severity Index version IV sum score;

EQ-5D NL score = three-level, five-dimensional EuroQol with the Dutch health utilities algorithm

applied (Lamers et al., 2006); QALYs is the averaged cumulative number of QALYs since baseline

per patient at the end of each time point, with QALYs based on the EQ-5D NL score; Societal costs

refers to the total societal costs in the 6 months prior to the data collection wave indicated by Time; all

results are based on multiple imputed data.

Table 4. Cost, remitted patients, QALYs and ICERs between baseline and 36 months after baseline

<i>Perspective/analysis</i>	MBT-DH (n = 54)			S-TAU (n = 41)			ICER	
	<i>Costs</i>	<i>Remitted</i>	<i>QALYs</i>	<i>Costs</i>	<i>Remitted</i>	<i>QALYs</i>	<i>€ per remission</i>	<i>€ per QALY</i>
Societal, MAR (base case)	€64,132	33%	1.29	€60,505	20%	1.49	€29,314	Dominated
Societal, MCAR	€58,316	37%	1.38	€55,353	23%	1.57	€26,122	Dominated
Healthcare sector, MAR	€61,222	33%	1.29	€58,670	20%	1.49	€22,106	Dominated

Note. This table presents mean costs, mean effects, and median incremental cost-effectiveness ratios (ICERs) for MBT-DH versus S-TAU from three different analytical perspectives. The base case scenario of this economic evaluation is performed from the societal perspective, using the data imputed under the MAR assumption. For the societal, MCAR analysis, missing data were imputed under the missing completely at random (MCAR) assumption. In the healthcare sector analysis (using the data imputed under the MAR assumption), BPD care costs (MBT-DH or S-TAU), medication costs, and all other healthcare costs besides MBT-DH or S-TAU were included. All results are based on analyses performed after bootstrapping.

Figure captions*Figure 1. Cost-effectiveness planes and cost-effectiveness acceptability curves*

Note. The two graphs at the top of this figure are cost-effectiveness planes. In these planes, the horizontal axis indicates differences in health gains between MBD-DH and S-TAU over 36 months, while the vertical axis represents differences in costs. The chart area is divided into quadrants, each with a specific interpretation. ICERs that fall into the upper right (“North East”) quadrant indicate that MBD-DH generated better health at additional costs; the lower left (“South West”) quadrant indicates less health gains for MBT-DH than S-TAU at lower costs. In the upper left (“North West”) quadrant, MBD-DH is dominated by S-TAU, as fewer health gains are obtained at higher costs for MBT-DH compared with S-TAU. In the lower right (“South East”) quadrant, MBD-DH dominates S-TAU with more health gains against lower costs.

The two plots at the bottom of this figure present cost-effectiveness acceptability curves. These curves show the probability that MBT-DH is more cost-effective than S-TAU as a function of the willingness to pay (WTP) for one additional unit of effect (one additional QALY or one additional person whose BPD remitted). The probability 0.50 on the vertical axis indicates the point of indifference. Above this indifference point, MBT-DH has a better likelihood of being preferred over S-TAU with regard to cost-effectiveness (with a likelihood equal to the probability on the vertical axis). As the WTP per unit of effect is generally an unknown quantity, it is presented as a series of increments on the horizontal axis.

Figure 2. Tornado plot for the main cost drivers of the base case model for remissions

Note. This plot indicates what the ICER with remission as an outcome would have been if the cost drivers presented on the vertical axis had been 20% higher or 20% lower than in the base case analysis. The ICER in the base case scenario is close to €29,000, as indicated by the vertical grey line that has a cross-section with the horizontal axis near that value. The cost model is sensitive to a misspecification in either BPD hospitalization costs or BPD day care costs, but not as sensitive to a misspecification of all BPD care costs simultaneously, or to any of the other cost categories.